Fisetin shows therapeutic efficacy in CRC via suppressing the PI3K/Akt/mTOR signaling, and fisetin combination with 5‐FU decreased the total number of intestinal tumors in the treatment of PIK3CA‐mutant CRC (Khan et al. 2019). The gene discussed is PIK3CA; the disease is colorectal carcinoma.